lecanemab Archives -

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with

Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go

https://pharmaphorum.com/news/exit-aduhelm-enter-lecanemab-biogen-and-eisai-have-another-go/

With prospects of an early, accelerated approval for Roche’s Alzheimer’s disease candidate gantenerumab looking diminished, the drugmaker has

Roche starts new four-year trial of Alzheimer’s drug gantenerumab

https://pharmaphorum.com/news/roche-starts-new-four-year-trial-of-alzheimers-drug-gantenerumab/

Biogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s

Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDA

https://pharmaphorum.com/news/biogen-eisai-alzheimers-drug-lecanemab-fast-tracked-by-fda/

Biogen and Eisai’s first Alzheimer’s disease drug Aduhelm is facing an uphill battle in the US market, but

Biogen, Eisai double down on Alzheimer’s with lecanemab filing

https://pharmaphorum.com/news/biogen-eisai-double-down-on-alzheimers-with-lecanemab-filing/

lecanemab